May 17, 2018 9:00 am EDT Atara Biotherapeutics to Present Long-Term Tab-cel™ Phase 2 Clinical Outcomes for Patients with Epstein-Barr Virus Associated Post-Transplant Lymphomas at 23rd Congress of European Hematology Association
May 08, 2018 7:05 am EDT Atara Biotherapeutics Announces First Quarter 2018 Financial Results and Recent Operational Progress
May 08, 2018 7:00 am EDT Atara Biotherapeutics Expands T-Cell Immunotherapy Collaboration to Advance Next-Generation CAR T Technologies in Oncology, Autoimmune and Other Diseases
May 07, 2018 5:30 pm EDT Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 07, 2018 8:00 am EDT Biotech Industry Veteran Dietmar Berger, M.D., Ph.D., Joins Atara Biotherapeutics as Global Head of Research and Development
May 01, 2018 8:00 am EDT Atara Biotherapeutics Expands Commercial Leadership Team with the Appointment of Manuela Maronati as General Manager, Europe
Apr 09, 2018 4:45 pm EDT Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Mar 22, 2018 4:30 pm EDT Atara Biotherapeutics to Participate in Three Upcoming Immuno-Oncology Conferences
Mar 16, 2018 8:00 am EDT Atara Biotherapeutics to Present at the 44th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT)
Mar 06, 2018 4:05 pm EST Atara Biotherapeutics to Present at the Cowen and Company 38th Annual Health Care Conference